Literature DB >> 12621380

An evaluation of the suitability of intravenous midazolam as an in vivo marker for hepatic cytochrome P4503A activity.

Janyce F Rogers1, Mario L Rocci, David B Haughey, Joseph S Bertino.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12621380     DOI： 10.1067/mcp.2003.23

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  22 in total

1.  Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration.

Authors:  Hong-yun Wang; Xia Chen; Ji Jiang; Jun Shi; Pei Hu
Journal:  Acta Pharmacol Sin       Date:  2015-11-23       Impact factor: 6.150

2.  Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients.

Authors:  C J Kirwan; I A M MacPhee; T Lee; D W Holt; B J Philips
Journal:  Intensive Care Med       Date:  2011-10-18       Impact factor: 17.440

3.  Lack of effect of subject posture on intravenous midazolam clearance: implications for hepatic cytochrome P450 3A phenotyping.

Authors:  Joseph D Ma; Anne N Nafziger; William Mylott; David B Haughey; Mario L Rocci; Joseph S Bertino
Journal:  Br J Clin Pharmacol       Date:  2008-12-12       Impact factor: 4.335

4.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

5.  Effects of Schisandra sphenanthera extract on the pharmacokinetics of midazolam in healthy volunteers.

Authors:  Hua-Wen Xin; Xiao-Chun Wu; Qing Li; Ai-Rong Yu; Lei Xiong
Journal:  Br J Clin Pharmacol       Date:  2009-02-04       Impact factor: 4.335

6.  Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.

Authors:  E D Kharasch; A Francis; A London; K Frey; T Kim; J Blood
Journal:  Clin Pharmacol Ther       Date:  2011-05-11       Impact factor: 6.875

7.  Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.

Authors:  David J Greenblatt; Diane E Peters; Lauren E Oleson; Jerold S Harmatz; Malcolm W MacNab; Noah Berkowitz; Miguel A Zinny; Michael H Court
Journal:  Br J Clin Pharmacol       Date:  2009-12       Impact factor: 4.335

8.  Polymorphism of CYP3A4 2 and eNOS genes in the diabetic patients with hyperlipidemia undergoing statin treatment.

Authors:  Kaiser Jamil; Vidya Kandula; Ramoji Kandula; M Asimuddin; Sindu Joshi; Shiva Kumar Yerra
Journal:  Mol Biol Rep       Date:  2014-07-05       Impact factor: 2.316

9.  Investigation of the in vivo activity of CYP3A in Brazilian volunteers: comparison of midazolam and omeprazole as drug markers.

Authors:  Adriana Rocha; Eduardo B Coelho; Soraia A P Moussa; Vera L Lanchote
Journal:  Eur J Clin Pharmacol       Date:  2008-06-26       Impact factor: 2.953

Review 10.  Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction.

Authors:  Roger K Verbeeck
Journal:  Eur J Clin Pharmacol       Date:  2008-09-02       Impact factor: 2.953
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.